Cite
MLA Citation
Zheng Xu et al.. “Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis.” Cancer medicine, vol. 8, n.d., pp. 629–642. http://access.bl.uk/ark:/81055/vdc_100084507822.0x000009